Sonoma Pharmaceuticals Inc.
SNOA
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.2M
Close$
$-2.92
326.5% downside
Current Fair Value
326.5% downsideOvervalued by 326.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.20 Million |
|---|---|
| Enterprise Value | $3.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.89 |
| Beta | 1.31 |
| Outstanding Shares | 3,846,000 |
Return
| Return on Equity | -34.33% |
|---|---|
| Return on Assets | -12.50% |
| Return on Invested Capital | -16.51% |
Valuation & Multiples
| P/E Ratio | -1.07 |
|---|---|
| PEG | 1.46 |
| Price to Sales | 0.26 |
| Price to Book Ratio | 1.29 |
| Enterprise Value to Revenue | 0.16 |
| Enterprise Value to EBIT | -1.68 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 1.9 |
| Debt to Equity | 1.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
$4.99 M
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.10
Average shareholder expectationRevenue Estimate
$5.29 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.88%▼ 1.13% |
|---|---|
| Total Invested | $136,262▼ 5.18% |
| Investors Holding | 14▼ 3.00% |
ESG Score
No data
About Sonoma Pharmaceuticals Inc.
CEO: Amy Trombly